@Ruby15 my experience has been in Debt Capital Markets not Equity Capital markets - but the syndication and book build process is much the same. Typically you would gauge interest before coming to market and try to shore up some cornerstone investors and then come to market knowing roughly the price range and demand for the issuance.
I'd say much of the book build is covered already and with 5mio shares of ¬60million shares on the market in free float there arent many available to trade. So if demand is strong this could well go through the guided range. Id argue they are leaving some juice on the table for cornerstone investors and if they are doing $4mio this last quarter then their growth rates have been strong in patient monitoring, and i expect further growth here to be the primary driver of revenue going forward.
Telehealth and Medtech are strong thematics globally at the moment and it is highly encouraging to see the improved guidance on revenue for USD$11mio this year.
Guthy Renker a strong endorsement for PRIZMA and expect product sales to start in this area as well. Much of my valuation is for IDTF and not product sales, so any improvement here is a kicker.....
And then of course NMPA and the 1bio of MOUs signed there yet to be played out......
im confident in my investment and the company is ticking boxes in terms of revenue growth and distribution agreements. The extra capital will help and shore up the business, but also should turbo charge growth.
Best of luck....going to be an interesting few months
